Preview

Epilepsia and paroxysmal conditions

Advanced search

THERAPEUTIC DRUG MONITORING OF LAMOTRIGINE: DEVELOPMENT OF PHARMACOKINETIC APPROACHES AIMING AT THE INDIVIDUAL-BASED ANTICONVULSIVE PHARMACOTHERAPY

Full Text:

Abstract

Abstract: this paper presents the results of therapeutic drug monitoring of lamotrigine, an anticonvulsant epilepsy medication, in patients with cryptogenic focal epilepsy using plasma and saliva as a biological material for drug testing. Comparative analysis of the steady-state plasma and saliva lamotrigine concentrations (СssMIN and СssMAX) allows the conclusion that saliva can be used as a suitable biological substrate for therapeutic drug monitoring.

About the Authors

D. A. Abaimov
The Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, Moscow
Russian Federation


A. K. Sariev
The Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, Moscow
Russian Federation


M. V. Tankevich
The Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, Moscow
Russian Federation


E. Yu. Styrova
The Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, Moscow
Russian Federation


V. V. Schvedkov
The Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, Moscow
Russian Federation


T. Yu. Noskova
The Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, Moscow
Russian Federation


R. D. Seifulla
The Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, Moscow
Russian Federation


References

1. Носкова Т.Ю. Ламотриджин в лечении эпилепсии у взрослых. Русский медицинский журнал. 2007; 15 (24).

2. Сычев К.С. Практическое руководство по жидкостной хроматографии. 2010; с. 216.

3. Dahl M., Wolf P., Khinchi M.S., Nielsen K.A. Lamotrigine therapeutic thresholds. Seizure. 2008; 17: 391-395

4. Garnett W. Lamotrigine: Pharmacokinetic. J. Child. Neurol. 1997; 12: 10-15.

5. Goldsmith D.R., Wagstaff A.J., Ibbotson T., Perry C.M.. Lamotrigine: A Review of its Use in Bipolar Disorder Drugs. 2003; 63: 2029-2050.

6. Greiner-Sosanko E., Lower D.R., Virji M.A., Krasowski M.D. Simultaneous determination of lamotrigine, zonisamide, and carbamazepine in human plasma by high-performance liquid chromatography. Biomed. Chromatogr. 2007; 21: 225-228.

7. Malone S., Eadie M., Addison R. Monitoring salivary lamotrigine concentrations. J. Clin. Neurosci. 2006; 13: 902-907.

8. Ryan M., Grim S., Miles M. et al. Correlation of lamotrigine concentrations between serum and saliva. Pharmacotherapy. 2003; 23: 1550-1557.

9. Tsiropoulos I., Kristensen O., Klitgaard N.A. Saliva and Serum Concentration of Lamotrigine in Patients With Epilepsy. Therapeutic Drug Monitoring. 2000; 22: 517-521.


For citation:


Abaimov D.A., Sariev A.K., Tankevich M.V., Styrova E.Y., Schvedkov V.V., Noskova T.Y., Seifulla R.D. THERAPEUTIC DRUG MONITORING OF LAMOTRIGINE: DEVELOPMENT OF PHARMACOKINETIC APPROACHES AIMING AT THE INDIVIDUAL-BASED ANTICONVULSIVE PHARMACOTHERAPY. Epilepsia and paroxysmal conditions. 2013;5(4):44-48. (In Russ.)

Views: 87


ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)